An analysis of the effectiveness of Travinor® in the treatment of primary open-angle glaucoma

Authors

  • L.P. Novak Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • N.S. Lavrik Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • S.I. Kosuba Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • N.V. Novak Kyiv City Clinical Ophthalmic Hospital “Center for Eye Microsurgery”, Kyiv, Ukraine
  • V.V. Cheb Kyiv City Clinical Ophthalmic Hospital “Center for Eye Microsurgery”, Kyiv, Ukraine
  • O.B. Horak Kyiv City Clinical Ophthalmic Hospital “Center for Eye Microsurgery”, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2309-8147.7.3.2019.179614

Keywords:

primary open-angle glaucoma, conservative treatment, prostaglandin analogues, travoprost, Heidelberg retinal tomography criteria for the diagnosis of glaucoma optic neuropathy

Abstract

Background. Normalization of intraocular pressure contributes to the long-term preservation of visual function in patients with primary open-angle glaucoma. Purpose: to study the efficacy of Travinor® (travoprost 0.004%) in the treatment of primary open-angle glaucoma and to analyze Heidelberg retinal tomography (HRT) criteria for the progression of glaucoma optic neuropathy. Materials and methods. There were 32 patients (48 eyes) with primary open-angle glaucoma stages I, II, and III under observation. All patients received Travinor® drops as monotherapy once daily (in the evening). The intraocular pressure, visual fields, and morphometric indices of the optic disc (HRT parameters) were evaluated over a three-month period. Results. Reduction of intraocular pressure on the background of Travinor® therapy was on average 6.7 mmHg after 1 month and 6.2 mmHg after 3 months. The most significant antihypertensive effect was observed on the background of Travinor® use in patients with primary open-angle glaucoma at the early stage — intraocular pressure decreased to 17.4 mmHg, at the moderate stage — to 20.1 mmHg, at the advanced stage — to 22 mmHg. Morphometry of the optic disc parameters based on morphofunctional tests was used as the criterion of efficiency when compared them before and against the background of Travinor® prescription. The most reliable criteria for evaluating the progression of glaucoma optic neuropathy were the following indicators of stereobiometry: the integral area of the neuroretinal rim, E/D index — the ratio of the linear diameter of the excavation to the diameter of the optic nerve, tolerance of the optic nerve, maximum depth of excavation. Conclusions. Travinor® is an effective and safe drug for the treatment of primary open-angle glaucoma.

Downloads

Download data is not yet available.

References

Аліфанова Т.А., Гладченко Ю.Ю., Чуйко О.Л. Інвалідність унаслідок патології органу зору в Україні. Філатовські читання: наук.-практ. конф. офтальмол. з міжнар. участю, присвяч. 75-річчю заснування Інституту ім. В.П. Філатова: тези доп. Одеса, 2011. С. 340.

Еричев В.П., Акопян А.И. Некоторые корреляционные взаимоотношения параметров ретинотомографического исследования. Глаукома. 2011. № 2. С. 24-28.

Еричев В.П. Основные направления гипотензивного лечения больных первичной глаукомой. Глаукома. 2015. № 3. С. 14-21.

Золотарев А.В., Карлова Е.В., Николаева Г.А. Участие различних слоев трабекулярного аппарата в осуществлении увеосклерального пути оттока с учетом их морфологических и топографических особенностей. Глаукома. 2016. № 1. С. 4-11.

Золотарев А.В., Карлова Е.В., Лебедев О.И., Столяров Г.М. Медикаментозная активация увеосклерального оттока внутриглазной жидкости при глаукоме. Вестник офтальмологии. 2013. Т. 129. № 4. С. 83-84.

Мочехин В.А., Маноенкова Г.Е. Параметры диска зрительного нерва при различных стадиях открытоугольной глаукомы по данным лазерного сканирующего ретинотомографа HRT. Глаукома. 2005. № 4. С. 3-9.

Нестеров А.П., Егоров Е.А. Медикаментозное гипотензивное лечение глаукомы. Клиническая фармакология и терапия. 2009. Т. 3. № 2. С. 86-88.

Nouri-Mahdavi K., Hoffman D., Coleman A.L. et al. Advanced Glaucoma Intervention Study. Predictive factors for glaucom atous visual field progression in the Advanced Glaucoma Intervention Study. Ophtalmology. 2014. Vol. 111. P. 1627-1635.

Shargorodskaya I.V., Gurskaya D.D., Lemeneva A.A., Simchuk I.V. Modern problems of medical treatment of glaucoma. Ophtalmology, Eastern Europe. 2014. № 23. P. 10-20.

Spry P.G., Sparrow J.M., Diamond J.P., Harris H.S. Risk factors for progressive visual field loss in primary open — angle glaucoma. Eye. 2005. Vol. 19. P. 643-651.

Quigley H.A., Addicks E.M., Green W.R., Maumenee A.E. Optic nerve damage in human glaucoma: The site of injury an suscepti bility to damage. Arch. Ophtalmol. 1981. Vol. 99. P. 635-649.

Weinreb R.N., Aung T., Medeiros F.A. The pathophysio­logy and treatment of glaucoma: a review. JAMA. 2014. 311. 1961-11. [PMID: 24825645].

Published

2021-09-28

Issue

Section

Clinical Ophthalmology

Most read articles by the same author(s)